SATB1 is a Novel Molecular Target for Cancer Therapy

References

• Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T. A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell. 1992;70:631–45. doi:10.1016/0092-8674(92)90432-C.
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 1999;9:40–48. doi:10.1016/S0959-437X(99)80006-9.
   PubMed Web of Science ®Google Scholar
• Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ, Botchkarev VA, Kohwi Y. Genome organizing function of SATB1 in tumor progression. Semin Cancer Biol. 2013;23:72–79. doi:10.1016/j.semcancer.2012.06.009.
   PubMed Web of Science ®Google Scholar
• Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T. SATB1 targets chromatin remodelling to regulate genes over long distances. Nature. 2002;419:641–5. doi:10.1038/nature01084.
   PubMed Web of Science ®Google Scholar
• Notani D, Limaye AS, Kumar PP, Galande S. Phosphorylation-dependent regulation of SATB1, the higher-order chromatin organizer and global gene regulator. Methods Mol Biol. 2010;647:317–35. doi:10.1007/978-1-60761-738-9_20.
   PubMedGoogle Scholar
• Wen J, Huang S, Rogers H, Dickinson LA, Kohwi-Shigematsu T, Noguchi CT. SATB1 family protein expressed during early erythroid differentiation modifies globin gene expression. Blood. 2005;105:3330–9. doi:10.1182/blood-2004-08-2988.
   PubMed Web of Science ®Google Scholar
• Cai S, Lee CC, Kohwi-Shigematsu T. SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet. 2006;38:1278–88. doi:10.1038/ng1913.
   PubMed Web of Science ®Google Scholar
• Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 2000;14:521–35.
   PubMed Web of Science ®Google Scholar
• Purbey PK, Singh S, Notani D, Kumar PP, Limaye AS, Galande S. Acetylation-dependent interaction of SATB1 and CtBP1 mediates transcriptional repression by SATB1. Mol Cell Biol. 2009;29:1321–37. doi:10.1128/MCB.00822-08.
   PubMed Web of Science ®Google Scholar
• Notani D, Gottimukkala KP, Jayani RS, Limaye AS, Damle MV, Mehta S, Purbey PK, Joseph J, Galande S. Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol. 2010;8:e1000296. doi:10.1371/journal.pbio.1000296.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Ji Y, Restifo NP. Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. Clin Cancer Res. 2010;16:4695–4701. doi:10.1158/1078-0432.CCR-10-0356.
   PubMed Web of Science ®Google Scholar
• Nodin B, Johannesson H, Wangefjord S, O'Connor DP, Lindquist KE, Uhlén M, Jirström K, Eberhard J. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer. Diagn Pathol. 2012;7:115. doi:10.1186/1746-1596-7-115.
   PubMed Web of Science ®Google Scholar
• Zheng J. Is SATB1 a master regulator in breast cancer growth and metastasis? Womens Health (Lond). 2008;4:329–32. doi:10.2217/17455057.4.4.329.
   PubMedGoogle Scholar
• Elebro J, Heby M, Gaber A, Nodin B, Jonsson L, Fristedt R, Uhlén M, Jirström K, Eberhard J. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. J Transl Med. 2014;12:289. doi:10.1186/s12967-014-0289-8.
   PubMed Web of Science ®Google Scholar
• Deng YF, Zhou DN, Pan ZY, Yin P. Aberrant SATB1 expression is associated with Epstein-Barr virus infection, metastasis and survival in human nasopharyngeal cells and endemic nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2014;7:2454–61.
   PubMedGoogle Scholar
• Han B, Luan L, Xu Z, Wu B. Expression and biological roles of SATB1 in human bladder cancer. Tumour Biol. 2013;34:2943–49. doi:10.1007/s13277-013-0857-1.
   PubMedGoogle Scholar
• Mao L, Yang C, Wang J, Li W, Wen R, Chen J, Zheng J. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med. 2013;11:111. doi:10.1186/1479-5876-11-111.
   PubMed Web of Science ®Google Scholar
• Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C, Kohonen-Corish MR. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011;6:1179–89. doi:10.1097/JTO.0b013e31821b4ce0.
   PubMed Web of Science ®Google Scholar
• Xiang J, Zhou L, Li S, Xi X, Zhang J, Wang Y, Yang Y, Liu X, Wan X. AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma. Oncol Lett. 2012;3:865–70.
   PubMed Web of Science ®Google Scholar
• Tu W, Luo M, Wang Z, Yan W, Xia Y, Deng H, He J, Han P, Tian D. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012;32:1064–78. doi:10.1111/j.1478-3231.2012.02815.x.
   PubMed Web of Science ®Google Scholar
• Agrelo R, Souabni A, Novatchkova M, Haslinger C, Leeb M, Komnenovic V, Kishimoto H, Gresh L, Kohwi-Shigematsu T, Kenner L, et al. SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev Cell. 2009;16:507–16. doi:10.1016/j.devcel.2009.03.006.
   PubMed Web of Science ®Google Scholar
• Cheng C, Wan F, Liu L, Zeng F, Xing S, Wu X, Chen X, Zhu Z. Overexpression of SATB1 is associated with biologic behavior in human renal cell carcinoma. PLoS One. 2014;9:e97406. doi:10.1371/journal.pone.0097406.
   PubMedGoogle Scholar
• Mir R, Pradhan S J, Galande S. Chromatin organizer SATB1 as a novel molecular target for cancer therapy. Curr Drug Targets. 2012;13:1603–15. doi:10.2174/138945012803530008.
   PubMed Web of Science ®Google Scholar
• Endo K, Shackelford J, Aga M, Yoshizaki T, Pagano JS. Upregulation of special AT-rich-binding protein 1 by Epstein-Barr virus latent membrane protein 1 in human nasopharyngeal cells and nasopharyngeal cancer. J Gen Virol. 2013;94:507–13. doi:10.1099/vir.0.046243-0.
   PubMed Web of Science ®Google Scholar
• Ye CS, Zhou DN, Yang QQ, Deng YF. Silencing SATB1 influences cell invasion, migration, proliferation, and drug resistance in nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2014;7:914–22.
   PubMed Web of Science ®Google Scholar
• Liu C X, Wen Y, Xu K, Zheng SB, Xu YW, Chen BS. [Expression of special AT-rich sequence-binding protein in bladder urothelial carcinoma and its clinical significance]. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30:1389–91.
   PubMedGoogle Scholar
• Nodin B, Hedner C, Uhlen M, Jirström K. Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. J Ovarian Res. 2012;5:24. doi:10.1186/1757-2215-5-24.
   PubMed Web of Science ®Google Scholar
• Zhao X L, Wang P. [Expression of SATB1 and BRMS1 in ovarian serous adenocarcinoma and its relationship with clinieopathological features]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2011;42:82–85.
   PubMedGoogle Scholar
• Li G, Yang D, Li X, Zhong K, Liu X, Bi M, Liu Y, Liao X, Lin L. [Expression of SATB1 in hepatocellular carcinoma cell lines with different invasive capacities]. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32:986–90.
   PubMedGoogle Scholar
• Peng Z K, Yang D H, Li X H, Huang Y, Zhang GQ, Zhong KB, Bi MP, Li GH. [Expression of special AT-rich sequence-binding protein 1 mRNA in hepatocellular carcinoma and its clinical significance]. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31:1207–11.
   PubMedGoogle Scholar
• Chu SH, Feng DF, Ma YB, Zhang H, Zhu ZA, Li ZQ, Jiang PC. Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. J Transl Med. 2011;9:156. doi:10.1186/1479-5876-9-156.
   PubMed Web of Science ®Google Scholar
• Chu SH, Ma YB, Feng DF, Li ZQ, Jiang PC. Correlation between SATB1 and Bcl-2 expression in human glioblastoma multiforme. Mol Med Rep. 2013;7(1):139–43. doi:10.3892/mmr.2012.1131.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gu X, Zhang G, Wang L, Wang T, Zhao Y, Zhang X, Zhou Y, Kadin M, Tu P. SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21. Blood. 2014;123:3452–61. doi:10.1182/blood-2013-10-534693.
   PubMed Web of Science ®Google Scholar
• Saad F, Pantel K. The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer. Future Oncol. 2012;8:321–31. doi:10.2217/fon.12.3.
   PubMed Web of Science ®Google Scholar
• Hsiao W, Moses KA, Goodman M, Jani AB, Rossi PJ, Master VA. Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease. J Urol. 2010;184:512–18. doi:10.1016/j.juro.2010.04.010.
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res. 2012;72:527–36. doi:10.1158/0008-5472.CAN-11-3004.
   PubMed Web of Science ®Google Scholar
• Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, et al. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med. 2011;9:185. doi:10.1186/1479-5876-9-185.
   PubMed Web of Science ®Google Scholar
• Shukla S, Sharma H, Abbas A, MacLennan GT, Fu P, Danielpour D, Gupta S. Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression. PLoS One. 2013;8:e53527. doi:10.1371/journal.pone.0053527.
   PubMed Web of Science ®Google Scholar
• Mao LJ, Zhang J, Liu N, Fan L, Yang DR, Xue BX, Shan YX, Zheng JN. Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis. Tumour Biol. 2015;36:9073–81. doi:10.1007/s13277-015-3658-x.
   PubMedGoogle Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.
   PubMed Web of Science ®Google Scholar
• Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, Cao M, Liu DM, Huang YR. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012;106:57–61. doi:10.1002/jso.23040.
   PubMed Web of Science ®Google Scholar
• Wan F, Cheng C, Wang Z, Xiao X, Zeng H, Xing S, Chen X, Wang J, Li S, Zhang Y, et al. SATB1 overexpression regulates the development and progression in bladder cancer through EMT. PLoS One. 2015;10:e0117518. doi:10.1371/journal.pone.0117518.
   PubMed Web of Science ®Google Scholar
• Planchat E, Durando X, Abrial C, Thivat E, Mouret-Reynier MA, Ferrière JP, Pomel C, Kwiatkowski F, Chollet P, Nabholtz JM. Prognostic value of initial tumor parameters after metastatic relapse. Cancer Invest. 2011;29:635–643. doi:10.3109/07357907.2011.621911.
   PubMed Web of Science ®Google Scholar
• Han H J, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008;452:187–93. doi:10.1038/nature06781.
   PubMed Web of Science ®Google Scholar
• Richon VM. A new path to the cancer epigenome. Nat Biotechnol. 2008;26:655–56. doi:10.1038/nbt0608-655.
   PubMed Web of Science ®Google Scholar
• Yamayoshi A, Yasuhara M, Galande S, Kobori A, Murakami A. Decoy-DNA against special AT-rich sequence binding protein 1 inhibits the growth and invasive ability of human breast cancer. Oligonucleotides. 2011;21:115–21. doi:10.1089/oli.2010.0277.
   PubMedGoogle Scholar
• Zhang S, Gao X, Ma Y, Jiang J, Dai Z, Yin X, Min W, Hui W, Wang B. Expression and significance of SATB1 in the development of breast cancer. Genet Mol Res. 2015;14:3309–17. doi:10.4238/2015.April.13.10.
   PubMed Web of Science ®Google Scholar
• Crepin M, Salle V, Raux H, Berger R, Hamelin R, Brouty-Boyé D, Israel L. Steroid hormone receptors and tumorigenicity of sublines from breast tumor metastatic MDA-MB 231 cell line. Anticancer Res. 1990;10:1661–66.
   PubMed Web of Science ®Google Scholar
• Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M. The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010;102:1284–96. doi:10.1093/jnci/djq243.
   PubMedGoogle Scholar
• Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113:775–82. doi:10.1097/AOG.0b013e31819cda77.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386. doi:10.1002/ijc.29210.
   PubMed Web of Science ®Google Scholar
• Kowalczyk AE, Godlewski J, Krazinski BE, Kiewisz J, Sliwinska-Jewsiewicka A, Kwiatkowski P, Pula B, Dziegiel P, Janiszewski J, Wierzbicki PM, et al. Divergent expression patterns of SATB1 mRNA and SATB1 protein in colorectal cancer and normal tissues. Tumour Biol. 2015;36:4441–52. doi:10.1007/s13277-015-3084-0.
   PubMedGoogle Scholar
• Meng WJ, Yan H, Li Y, Zhou ZG. SATB1 and colorectal cancer in Wnt/beta-catenin signaling: Is there a functional link? Med Hypotheses. 2011;76:277–9. doi:10.1016/j.mehy.2010.10.022.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhou J, Wang XY, Hao JM, Chen JZ, Zhang XM, Jin H, Liu L, Zhang YF, Liu J, et al. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009;219:114–22. doi:10.1002/path.2575.
   PubMed Web of Science ®Google Scholar
• Cai S, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet. 2003;34:42–51. doi:10.1038/ng1146.
   PubMed Web of Science ®Google Scholar
• Ma C, Zhang J, Durrin LK, Lv J, Zhu D, Han X, Sun Y. The BCL2 major breakpoint region (mbr) regulates gene expression. Oncogene. 2007;26:2649–57. doi:10.1038/sj.onc.1210069.
   PubMed Web of Science ®Google Scholar
• Li Q, Dashwood WM, Zhong X, Nakagama H, Dashwood RH. Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving beta-catenin, c-Myc and E2F1. Oncogene. 2007;26:6194–6202. doi:10.1038/sj.onc.1210438.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tian X, Ji H, Guan X, Xu W, Dong B, Zhao M, Wei M, Ye C, Sun Y, et al. Expression of SATB1 promotes the growth and metastasis of colorectal cancer. PLoS One. 2014;9:e100413. doi:10.1371/journal.pone.0100413.
   PubMed Web of Science ®Google Scholar
• Fromberg A, Rabe M, Aigner A. Multiple effects of the special AT-rich binding protein 1 (SATB1) in colon carcinoma. Int J Cancer. 2014;135:2537–46. doi:10.1002/ijc.28895.
   PubMed Web of Science ®Google Scholar
• Al-Sohaily S, Henderson C, Selinger C, Pangon L, Segelov E, Kohonen-Corish M, Warusavitarne J. Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer. Histopathology. 2014;65:155–63. doi:10.1111/his.12295.
   PubMed Web of Science ®Google Scholar
• Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010;7: 448–58. doi:10.1038/nrgastro.2010.100.
   PubMed Web of Science ®Google Scholar
• Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future. Semin Cancer Biol. 2011;21:59–69. doi:10.1016/j.semcancer.2010.11.002.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013;5:48–63. doi:10.3390/cancers5010048.
   PubMedGoogle Scholar
• Cheng C, Lu X, Wang G, Zheng L, Shu X, Zhu S, Liu K, Wu K, Tong Q. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS. 2010;118:855–63. doi:10.1111/j.1600-0463.2010.02673.x.
   PubMed Web of Science ®Google Scholar
• Lu X, Cheng C, Zhu S, Yang Y, Zheng L, Wang G, Shu X, Wu K, Liu K, Tong Q. SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncol Rep. 2010;24:981–7.
   PubMed Web of Science ®Google Scholar
• Sun F, Lu X, Li H, Peng Z, Wu K, Wang G, Tong Q. Special AT-rich sequence binding protein 1 regulates the multidrug resistance and invasion of human gastric cancer cells. Oncol Lett. 2012;4:156–162.
   PubMed Web of Science ®Google Scholar
• Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist. 2007;12:1096–1104. doi:10.1634/theoncologist.12-9-1096.
   PubMed Web of Science ®Google Scholar
• Huang B, Zhou H, Wang X, Liu Z. Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells. Cancer Cell Int. 2013;13:8. doi:10.1186/1475-2867-13-8.
   PubMed Web of Science ®Google Scholar
• Ruden E, Reardon DA, Coan AD, Herndon JE 2nd, Hornsby WE, West M, Fels DR, Desjardins A, Vredenburgh JJ, Waner E, et al. Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. J Clin Oncol. 2011;29:2918–23. doi:10.1200/JCO.2011.34.9852.
   PubMed Web of Science ®Google Scholar
• Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, Jiang PC. Correlation of low SLC22A18 expression with poor prognosis in patients with glioma. J Clin Neurosci. 2012;19:95–98. doi:10.1016/j.jocn.2011.04.032.
   PubMed Web of Science ®Google Scholar
• Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–61. doi:10.1016/S1470-2045(08)70125-6.
   PubMed Web of Science ®Google Scholar
• Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, Jiang PC. Upregulation of SATB1 is associated with the development and progression of glioma. J Transl Med. 2012;10:149. doi:10.1186/1479-5876-10-149.
   PubMed Web of Science ®Google Scholar